Amylou C. Dueck

2006–2025 年に発表

別表記
Amylou C Dueck
134
論文数
19,441
被引用数
74
h 指数
123
i10 指数

被引用数

Amylou C. Dueck の年別被引用数1996 年: 被引用 1 件2006 年: 被引用 1 件2007 年: 被引用 8 件2008 年: 被引用 13 件2009 年: 被引用 19 件2010 年: 被引用 38 件2011 年: 被引用 51 件2012 年: 被引用 59 件2013 年: 被引用 90 件2014 年: 被引用 103 件2015 年: 被引用 121 件2016 年: 被引用 154 件2017 年: 被引用 187 件2018 年: 被引用 196 件2019 年: 被引用 656 件2020 年: 被引用 909 件2021 年: 被引用 833 件2022 年: 被引用 699 件2023 年: 被引用 486 件2024 年: 被引用 921 件2025 年: 被引用 447 件2026 年: 被引用 12 件1997〜2005 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,367 件、この内訳の 25.2%イギリス: 引用元論文 712 件、この内訳の 7.6%イタリア: 引用元論文 546 件、この内訳の 5.8%ドイツ: 引用元論文 524 件、この内訳の 5.6%中国: 引用元論文 499 件、この内訳の 5.3%カナダ: 引用元論文 446 件、この内訳の 4.8%フランス: 引用元論文 405 件、この内訳の 4.3%オーストラリア: 引用元論文 342 件、この内訳の 3.7%オランダ: 引用元論文 341 件、この内訳の 3.6%スペイン: 引用元論文 320 件、この内訳の 3.4%スイス: 引用元論文 244 件、この内訳の 2.6%ベルギー: 引用元論文 243 件、この内訳の 2.6%
0%25.2%その他 25.5%

分野

  • Medicine78.6%
  • Biochemistry, Genetics and Molecular Biology9.2%
  • Health Professions3%
  • Psychology2.1%
  • Economics, Econometrics and Finance1.7%
  • Neuroscience1.2%
  • その他4.2%

トピック

  • Cancer survivorship and care7%
  • Breast Cancer Treatment Studies2.7%
  • HER2/EGFR in Cancer Research2.6%
  • Myeloproliferative Neoplasms: Diagnosis and Treatment2.6%
  • Advanced Breast Cancer Therapies2%
  • Cancer Immunotherapy and Biomarkers1.8%
  • その他81.3%

共著者

全論文

検索で開く
  1. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2015 被引用: 2,655

  2. Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2014 被引用: 1,127

  3. Preoperative Treatment of Locally Advanced Rectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 448

  4. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2022 被引用: 383

  5. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Otto Metzger, Anita Jallitsch-Halper, Kadine Solomon, Céline Schurmans, K. P. Theall, Dongrui R. Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L. Mayer, on behalf of the PALLAS groups and investigators - Journal of Clinical Oncology 2021 被引用: 231

  6. Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2015 被引用: 1,015

  7. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ashley Wilder Smith, Katherine M Soltys, Martin Taphoorn, Galina Velikova, Andrew Bottomley - The Lancet Oncology 2020 被引用: 306

  8. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer

    著者: , , , , , , - JAMA 2019 被引用: 567

  9. Sorafenib for Advanced and Refractory Desmoid Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 449

  10. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , E. Joanna Baxter, Mary Frances McMullin, Adam J. Mead - Journal of Clinical Oncology 2023 被引用: 142

  11. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Miguel Gil‐Gil, Aleix Prat, Hannes Fohler, Otto Metzger, Magdalena Schwarz, Carter DuFrane, Debora Fumagalli, Kathy Puyana Theall, Dongrui R. Lu, Cynthia Huang Bartlett, María Koehler, Christian Fesl, Angela DeMichele, Michael Gnant - The Lancet Oncology 2021 被引用: 255

  12. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joseph Tripodi, Noushin Farnoud, Alexander V. Penson, Rona Singer Weinberg, Leah Price, Judith D. Goldberg, Tiziano Barbui, Roberto Marchioli, Gianni Tognoni, Raajit K. Rampal, Ruben A. Mesa, Amylou C. Dueck, Ronald Hoffman - Blood 2022 被引用: 129

  13. Longitudinal Modeling of Age-Related Memory Decline and theAPOEε4 Effect

    著者: , , , , , , , , , , , , , , - New England Journal of Medicine 2009 被引用: 534

  14. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Francisco Cervantes, Peter Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Björn Andréasson, Maria L Ferarri, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegård, Ayalew Tefferi, Ruben A. Mesa - Journal of Clinical Oncology 2012 被引用: 458

  15. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 139

  16. A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment

    著者: , , , , , , , - Supportive Care in Cancer 2013 被引用: 323

  17. Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    著者: , , , , , , , , , , , , , , , , , , , - Clinical Trials 2020 被引用: 246

  18. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2016 被引用: 226

  19. Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial

    著者: , , , , , , , , , , , , , , , , , , , , , - JCO Clinical Cancer Informatics 2020 被引用: 193

  20. IAP antagonists induce anti-tumor immunity in multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2016 被引用: 171

  21. Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group

    著者: , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 68

  22. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 136

  23. Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant

    著者: , , , , , , , , , , , , , , , , - Transplantation and Cellular Therapy 2022 被引用: 64

  24. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)

    著者: , , , , , , , - Lung Cancer 2009 被引用: 218